{
 "as_of": "2026-11-08",
 "cmr": "us-cm-kg/NASDAQ/PHAR",
 "fence": "The page is the record's research on the issuer — no analyst, no rating, no view.",
 "markdown": "The page is the record's research on the issuer — no analyst, no rating, no view.\n\n# Pharming Group N.V. (NASDAQ: PHAR) — research page\n\nAs of 2026-11-08 · us-cm-kg · record version 1\n\n## Identity and listing\n\nThe issuer is Pharming Group N.V., listed on NASDAQ under ticker PHAR, with ISIN US71716E1055 and LEI 724500DCJ9MPG74JEH91. Its security type is recorded as non-operating entity type (other), and its segment is not on the record. Its sector is 2834 Pharmaceutical Preparations and its jurisdiction is the Netherlands. The issuer is listed and not halted.\n\n## The disclosure read\n\nThe record holds 25 filings in the window 2025-11-08 to 2026-11-08, on 23 filing days, all of type results. The median gap between filing days is 10.5 days. The latest filing is dated 2026-11-06, 2 days before the record date, and is of type results. The NASDAQ median cadence gap is 6.0 days with a median of 52 filings and a median latency of 5.0 days. The sector median cadence gap is 6.0 days with a median of 63.0 filings and a median latency of 4.0 days.\n\n## Auditor\n\nThe auditor is not on the record, because the latest annual report cover carries no dei:AuditorName tag. The auditor location is not on the record. The record holds no auditor changes.\n\n## Events and halts\n\nThe record holds no listing, delisting or name change events. The domicile change is not on the record, as EDGAR states no dated change of state of incorporation on a filing line. The segment move is not on the record, as the exchanges' tier transfers are not EDGAR filings. The issuer is listed and not halted.\n\n## Orderability\n\nThe outcome is not determinable, as the chapter's orderability section carries no client categories and so the outcome cannot name its client category. The rule version is acm-68000/us/reasonable-basis-suitability-finra-rule-2111/r1, with the chapter as of 2026-11-04.\n\n## Coverage\n\nThe record holds eight research houses named on the issuer's investor-relations page: Oppenheimer & Co. Inc., Portzamparc / BNP Paribas, Canaccord Genuity, First Berlin Research, H.C. Wainwright, Jefferies, Van Lanschot Kempen and RBC Capital Markets.\n\n## Open research\n\nNo openly published research notes were found on the record.\n\n## Licensed\n\nLicensed research: none loaded. A licensed row is served only to an agent whose firm holds that licence (licensor, entitlement). No licensed row is loaded.\n\n## As-of depth\n\nThe issuer's years sealed are 2021, 2022, 2023, 2024, 2025 and 2026. The market's earliest sealed date is 2021-01-04. The live record began on 2026-09-12.\n\n## Sources\n\n9 source pages are named on this page; every value above carries its own source page and read date in the numbers.\n\n- https://www.sec.gov/files/company_tickers_exchange.json (identity.exchange)\n- https://www.sec.gov/data-research/sec-markets-data/fails-deliver-data (identity.isin)\n- https://data.sec.gov/submissions/CIK0001828316.json (identity.jurisdiction)\n- https://mapping.gleif.org/api/v2/isin-lei/latest/download (identity.lei)\n- https://mcp.us-cm-kg.ai/events/NASDAQ/PHAR (the disclosure lines)\n- https://www.nasdaqtrader.com/rss.aspx?feed=tradehalts (the halt flag)\n- https://mcp.us-cm-kg.ai/book/aio.json (the orderability chapter)\n- https://www.pharming.com/investors/analyst-coverage (coverage)\n- https://mcp.us-cm-kg.ai/record/NASDAQ/PHAR (the record)\n",
 "market": "US",
 "node": "us-cm-kg",
 "numbers": {
  "as_of_depth": {
   "issuer_years_sealed": [
    "2021",
    "2022",
    "2023",
    "2024",
    "2025",
    "2026"
   ],
   "live_record_began": "2026-09-12",
   "node_history_from": "2021-01-04",
   "node_years_sealed": [
    "2021",
    "2022",
    "2023",
    "2024",
    "2025",
    "2026"
   ],
   "record_version": 1,
   "sealed": true
  },
  "auditor": {
   "auditor": {
    "market": "US",
    "reason": "no dei:AuditorName tag on the latest annual report cover (foreign private issuers and older filings carry none)",
    "state": "not_on_record"
   },
   "auditor_firm_id": {
    "market": "US",
    "state": "not_on_record"
   },
   "auditor_location": {
    "market": "US",
    "state": "not_on_record"
   },
   "changes": []
  },
  "cmr": "us-cm-kg/NASDAQ/PHAR",
  "coverage": {
   "count": 8,
   "houses": [
    {
     "analyst": "Joseph Pantginis",
     "house": "Oppenheimer & Co. Inc.",
     "read_by": "issuer IR page, fetched by this rail; each house name read on the page",
     "read_date": "2026-11-11",
     "source": "https://www.pharming.com/investors/analyst-coverage",
     "state": "sourced"
    },
    {
     "analyst": "Sushila Hernandez",
     "house": "Portzamparc / BNP Paribas",
     "read_by": "issuer IR page, fetched by this rail; each house name read on the page",
     "read_date": "2026-11-11",
     "source": "https://www.pharming.com/investors/analyst-coverage",
     "state": "sourced"
    },
    {
     "analyst": "Whitney Ijem",
     "house": "Canaccord Genuity",
     "read_by": "issuer IR page, fetched by this rail; each house name read on the page",
     "read_date": "2026-11-11",
     "source": "https://www.pharming.com/investors/analyst-coverage",
     "state": "sourced"
    },
    {
     "analyst": "Simon Scholes",
     "house": "First Berlin Research",
     "read_by": "issuer IR page, fetched by this rail; each house name read on the page",
     "read_date": "2026-11-11",
     "source": "https://www.pharming.com/investors/analyst-coverage",
     "state": "sourced"
    },
    {
     "analyst": "Joseph Pantginis",
     "house": "H.C. Wainwright",
     "read_by": "issuer IR page, fetched by this rail; each house name read on the page",
     "read_date": "2026-11-11",
     "source": "https://www.pharming.com/investors/analyst-coverage",
     "state": "sourced"
    },
    {
     "analyst": "Benjamin Jackson",
     "house": "Jefferies",
     "read_by": "issuer IR page, fetched by this rail; each house name read on the page",
     "read_date": "2026-11-11",
     "source": "https://www.pharming.com/investors/analyst-coverage",
     "state": "sourced"
    },
    {
     "analyst": "Sushila Hernandez",
     "house": "Van Lanschot Kempen",
     "read_by": "issuer IR page, fetched by this rail; each house name read on the page",
     "read_date": "2026-11-11",
     "source": "https://www.pharming.com/investors/analyst-coverage",
     "state": "sourced"
    },
    {
     "analyst": "Harry Sephton",
     "house": "RBC Capital Markets",
     "read_by": "issuer IR page, fetched by this rail; each house name read on the page",
     "read_date": "2026-11-11",
     "source": "https://www.pharming.com/investors/analyst-coverage",
     "state": "sourced"
    }
   ],
   "pages_checked": [
    {
     "page": "https://www.pharming.com/investors/analyst-coverage",
     "result": "read: 8 of 13 named houses found on the page"
    },
    {
     "page": "https://www.pharming.com/sites/default/files/imce/Press%20releases/Initiating-Coverage-Report-van-Leuwenhoeck.04.09.17.pdf",
     "result": "not readable by this rail (404)"
    }
   ],
   "read_by": "Perplexity sonar (search) · page read by this rail",
   "read_date": "2026-11-11",
   "since": "not stated on the page read",
   "state": "found"
  },
  "disclosure": {
   "against": {
    "exchange": {
     "issuers": 4359,
     "median_cadence_gap_days": 6,
     "median_filings": 52,
     "median_latency_days": 5,
     "name": "NASDAQ"
    },
    "sector": {
     "issuers": 526,
     "median_cadence_gap_days": 6,
     "median_filings": 63,
     "median_latency_days": 4,
     "name": "2834 Pharmaceutical Preparations"
    }
   },
   "by_type": {
    "results": 25
   },
   "cadence_median_gap_days": 10.5,
   "filing_days": 23,
   "filings": 25,
   "latency_days": 2,
   "latest": [
    {
     "category": "6-K",
     "date": "2026-11-06",
     "source": "https://www.sec.gov/Archives/edgar/data/1828316/000182831626000051/mhraapprovespharmingsjoenj.htm",
     "title": "6-K — 6-K",
     "type": "results"
    },
    {
     "category": "6-K",
     "date": "2026-10-27",
     "source": "https://www.sec.gov/Archives/edgar/data/1828316/000182831626000049/a2026q3pressrelease.htm",
     "title": "6-K — 6-K",
     "type": "results"
    },
    {
     "category": "6-K",
     "date": "2026-10-22",
     "source": "https://www.sec.gov/Archives/edgar/data/1828316/000182831626000047/q3announcementpr.htm",
     "title": "6-K — 6-K",
     "type": "results"
    },
    {
     "category": "6-K",
     "date": "2026-10-14",
     "source": "https://www.sec.gov/Archives/edgar/data/1828316/000182831626000045/pharmingpresentspositiveph.htm",
     "title": "6-K — 6-K",
     "type": "results"
    },
    {
     "category": "6-K",
     "date": "2026-09-29",
     "source": "https://www.sec.gov/Archives/edgar/data/1828316/000182831626000043/pharmingannouncesceotransi.htm",
     "title": "6-K — 6-K",
     "type": "results"
    }
   ],
   "latest_filing_date": "2026-11-06",
   "read": "the node's event lines (list_events_since), as get_filings serves them",
   "source": "https://mcp.us-cm-kg.ai/events/NASDAQ/PHAR",
   "window": {
    "from": "2025-11-08",
    "to": "2026-11-08"
   }
  },
  "identity": {
   "exchange": {
    "read_by": "EDGAR company_tickers_exchange.json (SEC list of exchange-listed filers)",
    "read_date": "2026-11-08",
    "read_date_basis": "the record version as_of",
    "source": "https://www.sec.gov/files/company_tickers_exchange.json",
    "state": "sourced",
    "value": "NASDAQ"
   },
   "isin": {
    "read_by": "SEC Fails-to-Deliver data (CUSIP for the symbol) · ISIN = US + CUSIP + ISO 6166 check digit",
    "read_date": "2026-09-25",
    "read_date_basis": "last_seen",
    "source": "https://www.sec.gov/data-research/sec-markets-data/fails-deliver-data",
    "state": "sourced",
    "value": "US71716E1055"
   },
   "jurisdiction": {
    "read_by": "EDGAR submissions API (issuer header as filed) (stateOfIncorporation)",
    "read_date": "2026-11-08",
    "read_date_basis": "the record version as_of",
    "source": "https://data.sec.gov/submissions/CIK0001828316.json",
    "state": "sourced",
    "value": "Netherlands"
   },
   "lei": {
    "read_by": "GLEIF ISIN-to-LEI mapping file (daily), LEI by exact ISIN",
    "read_date": "2026-11-08",
    "read_date_basis": "the field",
    "source": "https://mapping.gleif.org/api/v2/isin-lei/latest/download (ISIN US71716E1055)",
    "state": "sourced",
    "value": "724500DCJ9MPG74JEH91"
   },
   "name": {
    "read_by": "EDGAR submissions API (issuer header as filed)",
    "read_date": "2026-11-08",
    "read_date_basis": "the record version as_of",
    "source": "https://data.sec.gov/submissions/CIK0001828316.json",
    "state": "sourced",
    "value": "Pharming Group N.V."
   },
   "sector": {
    "read_by": "EDGAR submissions API (issuer header as filed) (SIC code as assigned by the SEC)",
    "read_date": "2026-11-08",
    "read_date_basis": "the record version as_of",
    "source": "https://data.sec.gov/submissions/CIK0001828316.json",
    "state": "sourced",
    "value": "2834 Pharmaceutical Preparations"
   },
   "security_type": {
    "read_by": "EDGAR submissions API (issuer header as filed)",
    "read_date": "2026-11-08",
    "read_date_basis": "the record version as_of",
    "source": "https://data.sec.gov/submissions/CIK0001828316.json",
    "state": "sourced",
    "value": "Non-operating entity type (other)"
   },
   "segment": {
    "market": "US",
    "state": "not_on_record"
   },
   "ticker": {
    "read_by": "EDGAR company_tickers_exchange.json (SEC list of exchange-listed filers)",
    "read_date": "2026-11-08",
    "read_date_basis": "the record version as_of",
    "source": "https://www.sec.gov/files/company_tickers_exchange.json",
    "state": "sourced",
    "value": "PHAR"
   },
   "website": {
    "market": "US",
    "state": "not_on_record"
   }
  },
  "licensed": {
   "columns": [
    "licensor",
    "entitlement",
    "title",
    "date",
    "source"
   ],
   "rows": [],
   "rule": "A licensed row is served only to an agent whose firm holds that licence (licensor, entitlement). No licensed row is loaded."
  },
  "lifecycle": {
   "delisting": [],
   "domicile_change": {
    "market": "US",
    "reason": "EDGAR states no dated change of state of incorporation on a filing line",
    "state": "not_on_record"
   },
   "listing": [],
   "name_change": [],
   "segment_move": {
    "market": "US",
    "reason": "the exchanges' tier transfers are not EDGAR filings",
    "state": "not_on_record"
   }
  },
  "market": "US",
  "node": "us-cm-kg",
  "numbers_hash": "sha256:330ce919654bb66d0d7172aa785997a8ca000e4d6630712ce3f9fede569e1904",
  "open_research": {
   "read_date": "2026-11-11",
   "rows": [],
   "state": "none_found"
  },
  "orderability": {
   "chapter_as_of": "2026-11-04",
   "client_categories": [],
   "determinable": false,
   "read": {
    "chapter": "https://mcp.us-cm-kg.ai/book/aio.json",
    "door": "https://mcp.us-cm-kg.ai/mcp",
    "tool": "get_orderability"
   },
   "reason": "the chapter's orderability section carries no client_categories: the outcome cannot name its client category",
   "rule_version": "acm-68000/us/reasonable-basis-suitability-finra-rule-2111/r1",
   "section": "us.aio.v8"
  },
  "record": {
   "as_of": "2026-11-08",
   "url": "https://mcp.us-cm-kg.ai/record/NASDAQ/PHAR",
   "version": 1
  },
  "schema": "research-numbers v0.1 (USR-01, 2026-11-11)",
  "status": {
   "read_date": "2026-11-08",
   "source": "https://www.nasdaqtrader.com/rss.aspx?feed=tradehalts",
   "value": "listed, not halted"
  }
 },
 "numbers_hash": "sha256:330ce919654bb66d0d7172aa785997a8ca000e4d6630712ce3f9fede569e1904",
 "path": "/us/NASDAQ/PHAR",
 "schema": "research-page v0.1 (USR-02, 2026-11-11)",
 "sections": [
  {
   "id": "identity",
   "text": "The issuer is Pharming Group N.V., listed on NASDAQ under ticker PHAR, with ISIN US71716E1055 and LEI 724500DCJ9MPG74JEH91. Its security type is recorded as non-operating entity type (other), and its segment is not on the record. Its sector is 2834 Pharmaceutical Preparations and its jurisdiction is the Netherlands. The issuer is listed and not halted.",
   "title": "Identity and listing"
  },
  {
   "id": "disclosure",
   "text": "The record holds 25 filings in the window 2025-11-08 to 2026-11-08, on 23 filing days, all of type results. The median gap between filing days is 10.5 days. The latest filing is dated 2026-11-06, 2 days before the record date, and is of type results. The NASDAQ median cadence gap is 6.0 days with a median of 52 filings and a median latency of 5.0 days. The sector median cadence gap is 6.0 days with a median of 63.0 filings and a median latency of 4.0 days.",
   "title": "The disclosure read"
  },
  {
   "id": "auditor",
   "text": "The auditor is not on the record, because the latest annual report cover carries no dei:AuditorName tag. The auditor location is not on the record. The record holds no auditor changes.",
   "title": "Auditor"
  },
  {
   "id": "events",
   "text": "The record holds no listing, delisting or name change events. The domicile change is not on the record, as EDGAR states no dated change of state of incorporation on a filing line. The segment move is not on the record, as the exchanges' tier transfers are not EDGAR filings. The issuer is listed and not halted.",
   "title": "Events and halts"
  },
  {
   "id": "orderability",
   "text": "The outcome is not determinable, as the chapter's orderability section carries no client categories and so the outcome cannot name its client category. The rule version is acm-68000/us/reasonable-basis-suitability-finra-rule-2111/r1, with the chapter as of 2026-11-04.",
   "title": "Orderability"
  },
  {
   "id": "coverage",
   "text": "The record holds eight research houses named on the issuer's investor-relations page: Oppenheimer & Co. Inc., Portzamparc / BNP Paribas, Canaccord Genuity, First Berlin Research, H.C. Wainwright, Jefferies, Van Lanschot Kempen and RBC Capital Markets.",
   "title": "Coverage"
  },
  {
   "id": "open_research",
   "text": "No openly published research notes were found on the record.",
   "title": "Open research"
  },
  {
   "id": "licensed",
   "text": "Licensed research: none loaded. A licensed row is served only to an agent whose firm holds that licence (licensor, entitlement). No licensed row is loaded.",
   "title": "Licensed"
  },
  {
   "id": "depth",
   "text": "The issuer's years sealed are 2021, 2022, 2023, 2024, 2025 and 2026. The market's earliest sealed date is 2021-01-04. The live record began on 2026-09-12.",
   "title": "As-of depth"
  },
  {
   "id": "sources",
   "text": "9 source pages are named on this page; every value above carries its own source page and read date in the numbers.",
   "title": "Sources"
  }
 ],
 "sources": [
  {
   "for": "identity.exchange",
   "source": "https://www.sec.gov/files/company_tickers_exchange.json"
  },
  {
   "for": "identity.isin",
   "source": "https://www.sec.gov/data-research/sec-markets-data/fails-deliver-data"
  },
  {
   "for": "identity.jurisdiction",
   "source": "https://data.sec.gov/submissions/CIK0001828316.json"
  },
  {
   "for": "identity.lei",
   "source": "https://mapping.gleif.org/api/v2/isin-lei/latest/download"
  },
  {
   "for": "the disclosure lines",
   "source": "https://mcp.us-cm-kg.ai/events/NASDAQ/PHAR"
  },
  {
   "for": "the halt flag",
   "source": "https://www.nasdaqtrader.com/rss.aspx?feed=tradehalts"
  },
  {
   "for": "the orderability chapter",
   "source": "https://mcp.us-cm-kg.ai/book/aio.json"
  },
  {
   "for": "coverage",
   "source": "https://www.pharming.com/investors/analyst-coverage"
  },
  {
   "for": "the record",
   "source": "https://mcp.us-cm-kg.ai/record/NASDAQ/PHAR"
  }
 ],
 "title": "Pharming Group N.V. (PHAR) — research page",
 "writer": {
  "by": "Claude through the platform account, Haiku class; one pass; checked against the numbers",
  "engine": "claude-haiku-5-5"
 }
}